Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects.
Sejung HwangDae Young LeeJoo-Youn ChoJae-Yong ChungIn-Jin JangKyung-Sang YuSeung Hwan LeePublished in: Drug design, development and therapy (2021)
After multiple oral doses of DA-8031 20, 30, and 40 mg in this study, the systemic exposure of DA-8031 increased in a more than dose-proportional manner with the increasing doses, and DA-8031 was generally well tolerated. In addition, the genetic polymorphisms of CYP2D6 have an impact on the pharmacokinetics of DA-8031.